Stock Events

Stock Events

GemVax & Kael 

₩8,680
2
+₩30+0.35% 06:19 Today

Statistics

Day High
8,740
Day Low
8,400
52W High
54,900
52W Low
8,400
Volume
133,231
Avg. Volume
156,988
Mkt Cap
384.25B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Apr 2008
₩150
Apr 2007
₩100
Apr 2006
₩50
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

May 13Expected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-389
-280
-171
-62
Expected EPS
N/A
Actual EPS
N/A

Financials

-13.9%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
81.53BRevenue
-11.34BNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap368.89B
Merck is a leading pharmaceutical company with a strong portfolio in oncology, including immunotherapy products that compete with GemVax's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb, with its extensive range of cancer treatments and focus on immuno-oncology, competes in the same therapeutic areas as GemVax.
Roche
RHHBY
Mkt Cap334.28B
Roche operates in the oncology segment with a broad portfolio, including targeted therapies and immunotherapies that rival GemVax's products.
Pfizer
PFE
Mkt Cap173.95B
Pfizer offers various oncology treatments, including immunotherapies, competing with GemVax in the cancer treatment market.
Novartis
NVS
Mkt Cap303.67B
Novartis provides advanced therapy platforms in oncology, directly competing with GemVax's cancer treatment and research efforts.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly and Company develops drugs for multiple types of cancer, competing with GemVax in the oncology pharmaceuticals market.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca has a strong focus on oncology, particularly in developing treatments for various cancers, which competes with GemVax's offerings.
AMGEN
AMGN
Mkt Cap251.94B
Amgen focuses on human therapeutics, including treatments for cancer, which places it in direct competition with GemVax in the oncology sector.

About

GemVax & KAEL Co., Ltd. specializes in manufacturing chemical filtration systems and gas purification units, primarily for the semiconductor industry. The company operates through two main segments: Environmental Pollution Control and Bio Business. Its Environmental Pollution Control division focuses on creating essential filters for semiconductor and display fabrication processes, in addition to developing equipment for air quality management and odor prevention. Concurrently, the Bio Business division is dedicated to advancing its innovative telomerase-derived peptide drug, GV1001, through preparations for domestic and international Phase 2 and 3 clinical trials. These trials are designed to address various conditions, including Alzheimer's disease, benign prostatic hyperplasia, and progressive supranuclear palsy. Founded on March 10, 1998, GemVax & KAEL Co., Ltd. is headquartered in Daejeon, South Korea.
Show More
CEO
Sang-Jae Kim
Employees
182
Country
South Korea
ISIN
KR7082270000

Listings

KQ
KR
082270.KQ

0 Comments

Share your thoughts

FAQs

What is GemVax & Kael stock price today?▼
The current price of 082270.KQ is ₩8,680 KRW — it has increased by +0.35% in the past 24 hours. Watch GemVax & Kael stock price performance more closely on the chart.
What is GemVax & Kael stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on KOSDAQ exchange GemVax & Kael stocks are traded under the ticker 082270.KQ.
Is GemVax & Kael stock price growing?▼
082270.KQ stock has fallen by -4.72% compared to the previous week, the month change is a -22.15% fall, over the last year GemVax & Kael has showed a -82.01% decrease.
What is GemVax & Kael market cap?▼
Today GemVax & Kael has the market capitalization of 384.25B
What is GemVax & Kael revenue for the last year?▼
GemVax & Kael revenue for the last year amounts to 81.53B KRW.
What is GemVax & Kael net income for the last year?▼
082270.KQ net income for the last year is -11.34B KRW.
Does GemVax & Kael pay dividends?▼
Yes, 082270.KQ dividends are paid annual. The last dividend per share was 150 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does GemVax & Kael have?▼
As of November 2, 2026, the company has 182 employees.
In which sector is GemVax & Kael located?▼
GemVax & Kael operates in the Manufacturing sector.
When did GemVax & Kael complete a stock split?▼
GemVax & Kael has not had any recent stock splits.
Where is GemVax & Kael headquartered?▼
GemVax & Kael is headquartered in Daejeon, South Korea.